Mediaboss Marketing

Of course, transparency and privacy concerns are significant, she notes, but if the information from our public health care system benefits everyone, is it inefficient to ask for consent for every use?

On the other hand, cybersecurity is another essential consideration, as weve come to learn that there are a lot of malevolent actors out there, says Miller Olafsson, with the potential ability to hack into centralized systems as part of a ransomware attack or other threat.

Even in its more basic uses, the potential of AI and machine learning is enormous. But the tricky part of using it in the health care sector is the need to have access to incredible amounts of data while at the same time understanding the sensitive nature of the data collected.

For artificial intelligence to be used in systems, procedures, or devices, you need access to data, and getting that data, particularly personal health information, is very challenging, says Carole Piovesan, managing partner at INQ Law in Toronto.

She points to the developing legal frameworks in Europe and North America for artificial intelligence and privacy legislation more generally. Lawyers working with start-up companies or health care organizations to build AI systems must help them stay within the parameters of existing laws, says Piovesan, and provide guidance on best practices for whatever may come down the line and help them deal with the potential risks.

Here is the original post:
Advances in AI and machine learning could lead to better health care: lawyers - Lexpert

Machine learning can enable positive change in society, says Adam Benzion, Chief Experience Officer at Edge Impulse. Read on to learn how the company is preventing unethical uses of its ML/AI development platform.

Machine learning can enable positive change in society, says Adam Benzion, Chief Experience Officer at Edge Impulse. Read on to learn how the company is preventing unethical uses of its ML/AI development platform.

Priscilla Haring-Kuipers: What Ethics in Electronics are you are working on?

Adam Benzion: At Edge Impulse, we try to connect our work to doing good in the world as a core value to our culture and operating philosophy. Our founders, Zach Shelby and Jan Jongboom define this as Machine learning can enable positive change in society, and we are dedicated to support applications for good. This is fundamental to what and how we do things. We invest our resources to support initiatives like UN Covid-19 Detect & Protect, Data Science Africa, and wildlife conservation with Smart Parks, Wildlabs, and ConservationX.

This also means we have a responsibility to prevent unethical uses of our ML/AI development platform. When Edge Impulse launched in January 2020, we decided to require a Responsible AI Licensefor our users, which prevents use for criminal purposes, surveillance, or harmful military or police applications. We have had a couple of cases where we have turned down a project that were not compatible with this license. There are also many positive uses for ML in governmental and defense applications, which we do support as compatible with our values.

We also joined 1% for the Planet, pledging to donate 1% of our revenue to support nonprofit organizations focused on the environment. I personally lead an initiative that focuses on elephant conservation where we have partnered with an organization called Smart Parks and helped developed a new AI-powered tracking collar that can last for eight years and be used to understand how the elephants communicate with each other. This is now deployed in parks across Mozambique.

Haring-Kuipers: What is the most important ethical question in your field?

Benzion: There are a lot of ethical issues with AI being used in population control, human recognition and tracking, let alone AI-powered weaponry. Especially where we touch human safety and dignity, AI-powered applications must be carefully evaluated, legislated and regulated. We dream of automation, fun magical experiences, and human-assisted technologies that do things better, faster and at a lesser cost. Thats the good AI dream, and thats what we all want to build. In a perfect world, we should all be able to vote on the rules and regulations that govern AI.

Haring-Kuipers: What would you like to include in an Electronics Code of Ethics?

Benzion: We need to look at how AI impacts human rights and machine accountability aka, when AI-powered machines fail, like in the case of autonomous driving, who takes the blame? Without universal guidelines to support us, it is up to every company in this field to find its core values and boundaries so we can all benefit from this exciting new wave.

Haring-Kuipers: An impossible choice ... The most important question before building anything is? A) Should I build this? B) Can I build this? C) How can I build this?

Benzion: A. Within reason, you can build almost anything, so ask yourself: Is the effort vs. outcome worth your precious time?

Priscilla Haring-Kuipers writes about technology from a social science perspective. She is especially interested in technology supporting the good in humanity and a firm believer in effect research. She has an MSc in Media Psychology and makes This Is Not Rocket Science happen.

Go here to see the original:
Machine Learning to Enable Positive Change An Interview with Adam Benzion - Elektor

Chicago, June 15, 2022 (GLOBE NEWSWIRE) -- According to the new market research report AI in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech, CROs) - Global Forecasts to 2027, published by MarketsandMarkets, the global Artificial Intelligence in Drug Discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period.

Browse in-depth TOC on Artificial Intelligence (AI) in Drug Discovery Market177 Tables 33 Figures 198 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151193446

The growth of this Artificial Intelligence in Drug Discovery Market is driven by the growing need to control drug discovery & development costs, and growing number of cross-industry collaborations and partnerships, On the other hand, a lack of data sets in the field of drug discovery and the inadequate availability of skilled labor are some of the factors challenging the growth of the market.

Services segment is expected to grow at the highest rate during the forecast period.

Based on offering, the AI in drug discovery market is segmented into software and services. In 2021, the services segment accounted for the largest market share of the global AI in drug discovery services market and also expected to grow at the highest CAGR during the forecast period. The benefits associated with AI services and the strong demand for AI services among end users are the key factors driving the growth of this market segment.

Machine learning technology segment accounted for the largest share of the global AI in drug discovery market.

Based on technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. The machine learning technology segment further segmented into deep learning, supervised learning. reinforcement learning, unsupervised learning, and other machine learning technologies. Deep learning segment accounted for the largest share of the market in 2021, and this segment also expected to grow at the highest CAGR during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=151193446

The immuno-oncology application segment accounted for the largest share of the AI in drug discovery market in 2021.

On the basis of application, the AI in drug discovery market is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular diseases, metabolic diseases, and other applications. The immuno-oncology segment accounted for the largest share of the market in 2021, owing to the increasing demand for effective cancer drugs. The neurodegenerative diseases segment is estimated to register the highest CAGR during the forecast period. The role of AI in resolving existing complexities in neurological drug development and strategic collaborations between pharmaceutical companies & solution providers are the key factors responsible for the high growth rate of the neurodegenerative diseases segment.

Pharmaceutical & biotechnology companies segment accounted for the largest share of the global AI in drug discovery market.

On the basis of end user, the AI in drug discovery market is segmented into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. The pharmaceutical & biotechnology companies segment accounted for the largest market share of AI in drug discovery market, in 2021, while the research centers and academic & government institutes segment is projected to register the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is driving the growth of this end-user segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=151193446

North America is expected to dominate the Artificial Intelligence in Drug Discovery Market in 2022.

North America accounted for the largest share of the global AI in drug discovery market in 2021 and also expected to grow at the highest CAGR during the forecast period. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the key factors responsible for the large share and high growth rate of this market

Top Key Players in Artificial Intelligence in Drug Discovery Market are:

Players in AI in Drug Discovery Market adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Browse Adjacent Markets:Healthcare IT Market Research Reports & Consulting

Browse Related Reports:

Drug Discovery Services Market by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) - Global Forecast to 2026https://www.marketsandmarkets.com/Market-Reports/drug-discovery-services-market-138732129.html

Artificial Intelligence In Genomics Market by Offering (Software, Services),Technology (Machine Learning, Computer Vision), Functionality (Genome Sequencing, Gene Editing), Application (Diagnostics), End User (Pharma, Research)-Global Forecasts to 2025https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-in-genomics-market-36649899.html

Continue reading here:
Artificial Intelligence in Drug Discovery Market worth $4.0 billion by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire

Accel Solutions and Veego today announced the integration of Veego's Artificial Intelligence and machine learning solution with Bezeq, Israel's largest Telecom. The integration will enhance Bezeq's ability to provide its subscribers with improved Internet quality of experience and mitigate network malfunctions. Bezeq will integrate Veego's solution in their consumer line of Be-Routers. The Veego solution provides Bezeq the ability to identify and mitigate connectivity malfunctions remotely, attain a broad overview of the network and improve the overall experience for its customers.

Niv Berkner, Head of Services and Product Innovation at Bezeq indicated "I have no doubt that the integration of the Veego solution in our Be-Routers will allow us to provide our customers an optimal quality of experience. The Veego solution will allow us to understand the interaction between all the devices connected in the home, and as such, provide Bezeq the ability to identify, anticipate and mitigate network related malfunctions remotely, without the customers involvement and/or being aware."

"Veego provides ISPs and CSPs the ability to leverage data and provide them with insights that alleviate churn, while constantly improving the customer experience." outlined Amir Kotler, Veego's CEO.

"The integration of Veego's AI and ML capabilities enable Telcos to actually experience what the customer experiences when he has an internet malfunction that disrupts a healthy Internet process," Kotler added "Veego's solution enables ISP to predict the issue, resolve it in autonomic ways and as a result, improves operational efficiency, increases revenues and reduces churn."

Ronen Shor, CEO of Accel Solutions stated, "The Bezeq - Veego agreement is another step in our continuous enhancement efforts on the products sold to Bezeq and a significant technological upgrade offered by Bezeq to its customers. Accel Solutions considers Veego as a strategic partner with tremendous potential in the international market.

Source:https://accelsolutionsllc.com/

Go here to read the rest:
Veegos Artificial Intelligence and Machine Learning Solution Integrated with Israels Largest Telecom - AZoRobotics

The advisory and climate tech-led sustainability solution has opened a new London HQ after raising $5m in a pre-Series A funding round, to support growing demand from commercial and industrial UK real estate owners striving to meet net zero carbon targets

Ecolibriums Head of Commercial Real Estate Yash Kapila (left) and CEO Chintan Soni (right) will lead the business UK expansion from its new London HQ. Image credit: Max Lacome

UK expansion builds on considerable success in Asia Pacific, where Ecolibrium's technology has been deployed across 50 million sq ft by globally renowned brands including Amazon, Fiat, Honeywell, Thomson Reuters, Tata Power, and the Delhi Metro

The $5m pre-Series A funding round was co-led by Amit Bhatia's Swordfish Investments and Shravin Bharti Mittal's Unbound venture capital firm

Launches in the UK today having already signed its first commercial contract with Integral, real estate giant JLL's engineering and facilities service business

LONDON, June 13, 2022 /PRNewswire/ -- Machine learning-led decarbonisation platform Ecolibrium has today launched its revolutionary sustainability solution in the UK, as the race to reduce carbon emissions accelerates across the built environment.

Founded in 2008 by entrepreneur brothers Chintan and Harit Soni at IIM Ahmedabad's Centre for Innovation, Incubation and Entrepreneurship in India, Ecolibrium provides expert advisory as well as technology-driven sustainability solutions to enable businesses in commercial and industrial real estate to reduce energy consumption and ultimately achieve their net zero carbon ambitions.

Relocating its global headquarters to London, Ecolibrium has raised $5m in a pre-Series A funding round as it looks to expand its international footprint to the UK. The round was co-led by Amit Bhatia's Swordfish Investments and Shravin Bharti Mittal's Unbound venture capital firm, alongside several strategic investors.

Ecolibrium launches in the UK today having already signed its first commercial contract with Integral, JLL's UK engineering and facilities service business.

The fundraising and UK expansion builds on Ecolibrium's considerable success in Asia Pacific, where its technology is being used across 50 million sq ft by more than 150 companies including Amazon, Fiat, Honeywell, Thomson Reuters, Tata Power, and the Delhi Metro. An annual reduction of 5-15% in carbon footprint has been achieved to date by companies which have deployed Ecolibrium's technology.

Story continues

Ecolibrium has also strengthened its senior UK management team, as it prepares to roll-out its green platform across the UK, by hiring facilities and asset management veteran Yash Kapila as its new head of commercial real estate. Kapila previously held senior leadership positions with JLL across APAC and EMEA regions.

Introducing SmartSense

At the heart of Ecolibrium's offer is its sustainability-led technology product SmartSense, which assimilates thousands of internet of things (IoT) data points from across a facility's entire energy infrastructure.

This information is then channelled through Ecolibrium's proprietary machine learning algorithms, which have been developed over 10 years by their in-house subject matter experts. Customers can visualise the data through a bespoke user interface that provides actionable insights and a blueprint for achieving operational excellence, sustainability targets, and healthy buildings.

This connected infrastructure generates a granular view of an asset's carbon footprint, unlocking inefficiencies and empowering smart decision-making, while driving a programme of continuous improvement to deliver empirical and tangible sustainability and productivity gains.

Preparing for future regulation

Quality environmental data and proof points are also providing a distinct business advantage at this time of increasing regulatory requirements that require corporates to disclose ESG and sustainability performance. Ecolibrium will work closely with customers to lead the way in shaping their ESG governance.

According to Deloitte, with a minimum Grade B Energy Performance Certification (EPC) requirement anticipated by 2030, 80% of London office stock will need to be upgraded an equivalent of 15 million sq ft per annum.

Research from the World Economic Forumhas found that the built environment is responsible for 40% of global energy consumption and 33% of greenhouse gas emissions, with one-fifth of the world's largest 2,000 companies adopting net zero strategies by 2050 or earlier. Technology holds the key to meeting this challenge, with Ecolibrium and other sustainability-focused changemakers leading the decarbonisation drive.

Chintan Soni, Chief Executive Officer at Ecolibrium, said:"Our mission is to create a balance between people, planet and profit and our technology addresses each of these objectives, leading businesses to sustainable prosperity. There is no doubt the world is facing a climate emergency, and we must act now to decarbonise and protect our planet for future generations.

"By using our proprietary machine learning-led technology and deep in-house expertise, Ecolibrium can help commercial and industrial real estate owners to deliver against ESG objectives, as companies awaken to the fact that urgent action must be taken to reduce emissions and achieve net zero carbon targets in the built environment.

"Our goal is to partner with companies and coach them to work smarter, make critical decisions more quickly and consume less. And, by doing this at scale, Ecolibrium will make a significant impact on the carbon footprint of commercial and industrial assets, globally."

The UK expansion has been supported by the Department for International Trade's Global Entrepreneur Programme. The programme has provided invaluable assistance in setting up Ecolibrium's London headquarters and scaling in the UK market.

In turn, Ecolibrium is supporting the growth of UK innovation, promoting green job creation, and providing tangible economic benefits, as part of the country's wider transition to a more sustainable future.

Minister for Investment Lord Grimstone said: "Tackling climate change is crucial in our quest for a cleaner and green future, something investment will play an important part in.

"That's why I'm pleased to see Ecolibrium's expansion to the UK. Not only will the investment provide a revolutionary sustainability solution to reduce carbon emissions across various sectors, it is a continued sign of the UK as a leading inward investment destination, with innovation and expertise in our arsenal".

About Ecolibrium

Ecolibrium is a machine learning-led decarbonisation platform balancing people, planet and profit to deliver sustainable prosperity for businesses.

Founded in 2008 by entrepreneur brothers Chintan and Harit Soni, Ecolibrium provides expert advisory as well as technology-driven sustainability solutions to enable commercial and industrial real estate owners to reduce energy consumption and ultimately achieve their net zero carbon ambitions.

Ecolibrium's flagship technology product SmartSense is currently being used across 50 million sq ft by more than 150 companies including JLL, Amazon, Fiat, Honeywell, Thomson Reuters, Tata Power, and the Delhi Metro. SmartSense collects real-time information on assets, operational data and critical metrics using internet of things (IoT) technology. This intelligence is then channelled through Ecolibrium's proprietary machine learning algorithms to visualise data and provide actionable insights to help companies make transformative changes to their sustainability goals.

For more information, visit: http://www.ecolibrium.io

For press enquiries, contact: FTI Consulting: ecolibrium@fticonsulting.com, +44 (0) 2037271000

Photo - https://mma.prnewswire.com/media/1837227/Ecolibrium_Yash_Kapila_and_Chintan_Soni.jpg

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/machine-learning-led-decarbonisation-platform-ecolibrium-launches-in-the-uk-301566340.html

SOURCE Ecolibrium

Original post:
Machine learning-led decarbonisation platform Ecolibrium launches in the UK - Yahoo Finance